Source: Getty Images Enfortumab vedotin produced a response in 23.9% of patients. One patient achieved a complete response, and 10 had a partial response. Enfortumab vedotin may be a treatment option ...
First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...
Public health authorities worry that Trump's victory could lead to increases in preventable illnesses, a weakening of public confidence in established science, and policies backed by debunked ideas.
Lack of health insurance coverage accounts for a considerable proportion of racial and ethnic disparities in the diagnosis of advanced-stage cancer, according to researchers.